Sequence variation in mitochondrial complex I genes: mutation or polymorphism?
- 1Mitochondrial Research Group, School of Neurology, Neurobiology and Psychiatry, University of Newcastle upon Tyne, UK
- 2Department of Radiation Oncology, University of Texas Medical Branch, Galveston, Texas, USA
- Correspondence to: Professor D M Turnbull Mitochondrial Research Group, School of Neurology, Neurobiology and Psychiatry, The Medical School, University of Newcastle upon Tyne, Newcastle upon Tyne NE2 4HH, UK;
- Received 3 March 2005
- Accepted 9 June 2005
- Revised 23 May 2005
- Published Online First 21 June 2005
Background: Defects of the mitochondrial genome are recognised as common causes of genetic disease. Sequencing of large portions or even the entire mitochondrial genome is routine in many laboratories for the investigation of mitochondrial disease. However, establishing whether a detected sequence change is polymorphic or pathogenic is still a major difficulty because of its highly polymorphic nature. This has major implications for the patient and the family.
Objective: To describe a scoring system for determining the likelihood that a given sequence variant in one of the seven mitochondrially encoded complex I (MTND) genes is truly pathogenic.
Results: The scoring system was applied to 50 reported MTND mutations. Using this system, 21 of the mutations analysed fell into the group of neutral sequence variants, 10 were classified as possibly pathogenic, three as probably pathogenic, and 16 as almost certainly pathogenic.
Conclusions: The proposed scoring system should advance the interpretation of sequence variants and ensure that candidate pathogenic mutations are rigorously investigated.
- LHON, Leber’s hereditary optic neuropathy
- MELAS, mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes
- mtDNA, mitochondrial DNA
Conflicts of interest: none declared